ES2603532T3 - Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica - Google Patents

Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica Download PDF

Info

Publication number
ES2603532T3
ES2603532T3 ES10182544.6T ES10182544T ES2603532T3 ES 2603532 T3 ES2603532 T3 ES 2603532T3 ES 10182544 T ES10182544 T ES 10182544T ES 2603532 T3 ES2603532 T3 ES 2603532T3
Authority
ES
Spain
Prior art keywords
seq
acid sequence
protein
amino acid
mature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10182544.6T
Other languages
English (en)
Spanish (es)
Inventor
W. Zlotnick Gary
Leah D. Fletcher
John Farley
Liesel A. Bernfield
J Zagursky Robert
Benjamin J. Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2603532(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Application granted granted Critical
Publication of ES2603532T3 publication Critical patent/ES2603532T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
ES10182544.6T 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica Expired - Lifetime ES2603532T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32810101P 2001-10-11 2001-10-11
US328101P 2001-10-11
US40693402P 2002-08-30 2002-08-30
US406934P 2002-08-30

Publications (1)

Publication Number Publication Date
ES2603532T3 true ES2603532T3 (es) 2017-02-28

Family

ID=27668840

Family Applications (14)

Application Number Title Priority Date Filing Date
ES10182544.6T Expired - Lifetime ES2603532T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182437.3T Expired - Lifetime ES2532639T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES02804818.9T Expired - Lifetime ES2568895T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182469.6T Expired - Lifetime ES2625876T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182487.8T Expired - Lifetime ES2615206T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182611.3T Expired - Lifetime ES2562811T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182364.9T Expired - Lifetime ES2609039T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182298.9T Expired - Lifetime ES2593360T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10183020.6T Expired - Lifetime ES2532640T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182399.5T Expired - Lifetime ES2603531T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182590.9T Expired - Lifetime ES2561430T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182324.3T Expired - Lifetime ES2549764T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES17156888T Expired - Lifetime ES2781213T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182345.8T Expired - Lifetime ES2549765T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica

Family Applications After (13)

Application Number Title Priority Date Filing Date
ES10182437.3T Expired - Lifetime ES2532639T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES02804818.9T Expired - Lifetime ES2568895T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182469.6T Expired - Lifetime ES2625876T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182487.8T Expired - Lifetime ES2615206T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182611.3T Expired - Lifetime ES2562811T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182364.9T Expired - Lifetime ES2609039T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182298.9T Expired - Lifetime ES2593360T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10183020.6T Expired - Lifetime ES2532640T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182399.5T Expired - Lifetime ES2603531T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182590.9T Expired - Lifetime ES2561430T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182324.3T Expired - Lifetime ES2549764T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES17156888T Expired - Lifetime ES2781213T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182345.8T Expired - Lifetime ES2549765T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica

Country Status (18)

Country Link
US (13) US8101194B2 (en:Method)
EP (14) EP2371838B1 (en:Method)
JP (6) JP2005515771A (en:Method)
KR (4) KR101215664B1 (en:Method)
CN (4) CN102755631B (en:Method)
AU (3) AU2009213040C1 (en:Method)
BE (3) BE2017C055I2 (en:Method)
BR (1) BRPI0212999B8 (en:Method)
CA (5) CA2939781C (en:Method)
DK (10) DK2371836T3 (en:Method)
ES (14) ES2603532T3 (en:Method)
FR (4) FR15C0056I2 (en:Method)
IL (5) IL161052A0 (en:Method)
LU (4) LU92786I2 (en:Method)
MX (3) MX339524B (en:Method)
NL (3) NL300896I2 (en:Method)
PT (10) PT2341062T (en:Method)
WO (1) WO2003063766A2 (en:Method)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330838C (en) 1998-05-01 2018-12-04 Chiron Corporation Neisseria meningitidis antigens and compositions
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
MXPA02004283A (es) 1999-10-29 2002-10-17 Chiron Spa Peptidos antigenicos neisseriales.
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
DK2270030T3 (da) 2000-02-28 2012-08-13 Novartis Vaccines & Diagnostic Heterolog ekspression af Neisseria-proteiner
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ES2775098T3 (es) 2002-10-11 2020-07-23 Glaxosmithkline Biologicals Sa Vacunas de polipéptidos para protección amplia contra linajes meningocócicos hipervirulentos
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
PT2191844E (pt) 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
CN1867354A (zh) * 2003-04-16 2006-11-22 惠氏控股有限公司 预防和治疗脑膜炎球菌疾病的新颖免疫原性组合物
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
AU2006263936B2 (en) 2005-06-27 2010-05-20 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CN101535493A (zh) 2006-07-27 2009-09-16 惠氏公司 用于生产重组蛋白质的高细胞密度补料-分批发酵方法
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
AU2010227220B2 (en) * 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
BR112012004276A2 (pt) 2009-08-27 2017-10-24 Novartis Ag adjuvante compreendendo alumínio, oligonucleotídeo e policátion
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
HUE048398T2 (hu) 2010-06-04 2020-07-28 Wyeth Llc Vakcinakészítmények
EP2585106A1 (en) * 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
BR112014016223A8 (pt) * 2011-12-29 2017-07-04 Novartis Ag combinações adjuvantes de proteínas de ligação de fator h meningocócico
CN104114706A (zh) 2012-02-02 2014-10-22 诺华股份有限公司 用于脑膜炎球菌中增加的蛋白表达的启动子
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
NZ628449A (en) * 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013276083B2 (en) 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
SG11201600334SA (en) 2013-08-02 2016-02-26 Children S Hospital & Res Ct Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
BR112016004463A2 (pt) * 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
EP3172224B1 (en) 2014-07-23 2022-06-29 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
US11031102B2 (en) 2014-11-17 2021-06-08 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
CN106434720A (zh) * 2016-08-03 2017-02-22 中国医学科学院医学生物学研究所 提高脑膜炎奈瑟菌fHBP蛋白表达的方法
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
CN111316161B (zh) * 2017-09-28 2021-11-23 富士胶片株式会社 摄像装置、信息获取方法及信息获取程序
CN111133378B (zh) 2017-09-28 2021-04-23 富士胶片株式会社 摄像装置、信息获取方法及记录介质
TWI687696B (zh) * 2019-06-26 2020-03-11 國立中興大學 回饋型隱藏式馬可夫模型辨識器的建立方法與基於此辨識器的辨識系統的建立方法
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
CN114681601B (zh) * 2020-12-31 2025-08-19 基础治疗有限公司 脑膜炎奈瑟氏球菌疫苗及其应用
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
CN118613207A (zh) 2022-01-24 2024-09-06 皇家飞利浦有限公司 使用血管内数据与管腔外图像之间的共配准的脉搏波速度确定以及相关联的系统、设备和方法
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
CN120241991A (zh) * 2025-06-05 2025-07-04 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT280356B (de) 1968-03-06 1970-04-10 Telefonbau & Normalzeit Gmbh Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it) * 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4668829A (en) * 1984-07-18 1987-05-26 University Patents, Inc. Ferroelectric smectic liquid crystals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
JPH01144977A (ja) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
WO1989007150A1 (en) 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5601831A (en) * 1989-03-09 1997-02-11 Praxis Biologics, Inc. Vaccines for nontypable Haemophilus influenzae
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
JPH0453645U (en:Method) * 1990-09-12 1992-05-07
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993007897A1 (en) 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (en) 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
DE69434079T2 (de) * 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
EP0689603A1 (en) 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
HU216871B (hu) 1993-07-13 1999-09-28 Rhone-Poulenc Rorer S.A. Defektív adenovírusvektorok és génterápiai alkalmazásuk
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
EP0711354A1 (en) 1993-07-30 1996-05-15 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FI98045C (fi) 1994-02-21 1997-04-10 Arto Remes Laite inkontinenssihoitoa varten
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
WO1995026411A2 (en) 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995028494A1 (en) 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
EP0710118B1 (en) * 1994-04-20 1998-11-25 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
AU6043396A (en) 1995-06-05 1996-12-24 University Of Alabama At Birmingham Research Foundation, The Composition and methods for creating syngeneic recombinant v irus-producing cells
CA2223300C (en) * 1995-06-07 2010-07-27 Connaught Laboratories, Inc. Expression of lipoproteins
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
DE69725739T2 (de) 1996-08-27 2004-08-05 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (de) * 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
JP2002515816A (ja) 1997-06-30 2002-05-28 アバンテイス・フアルマ・エス・アー ｉｎ ｖｉｖｏ組織に核酸ベクターを最適に電気導入する装置
EP0991425B1 (fr) 1997-06-30 2005-03-09 Institut Gustave Roussy Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede
PL337583A1 (en) 1997-06-30 2000-08-28 Rhone Poulenc Rorer Sa Improved method of transferring nucleic acid to a striated muscle and connection enabling accomplishment of this method
BR9811475A (pt) * 1997-07-17 2000-08-15 North American Vaccine Inc Conjugados imunogênicos compreendendo uma porina meningocóccica de grupo b e um polissacarìdeo de h. influenzae
JPH1144977A (ja) 1997-07-25 1999-02-16 Copyer Co Ltd 画像形成装置
PT1007546E (pt) 1997-08-27 2009-04-24 Childrens Hosp & Res Ct Oak Compostos miméticos moleculares de epítopos de meningococos do serogrupo b
US6207775B1 (en) * 1997-08-29 2001-03-27 The Dow Chemical Company Homogeneous filled polymer composite
WO1999024578A2 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CN1597694A (zh) 1998-01-14 2005-03-23 启龙股份公司 脑膜炎奈瑟氏球菌抗原
ES2334185T3 (es) * 1998-02-03 2010-03-05 Center For Disease Control And Prevention Proteina psaa lipidada recombinante, procedimientos de preparacion y uilizacion.
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
CA2330838C (en) 1998-05-01 2018-12-04 Chiron Corporation Neisseria meningitidis antigens and compositions
DE69934225T2 (de) 1998-05-29 2007-09-27 Novartis Vaccines and Diagnostics, Inc., Emeryville Kombinierte meningitis b/c impfstoffe
EP1198245B1 (en) 1998-09-30 2004-08-25 Walter Reed Army Institute of Research Use of purified invaplex from gram negative bacteria as a vaccine
ES2293735T3 (es) 1998-09-30 2008-03-16 Wyeth Holdings Corporation Holotoxina del colera mutante como coadyuvante.
CN1338005A (zh) 1998-10-09 2002-02-27 希龙公司 奈瑟球菌基因组序列及其用途
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
WO2000042192A1 (en) 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis polypeptide basb052
EP1147194A1 (en) 1999-01-22 2001-10-24 SMITHKLINE BEECHAM BIOLOGICALS s.a. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
DE60040727D1 (de) 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
ES2228454T3 (es) 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
JP2003527079A (ja) 1999-04-30 2003-09-16 カイロン コーポレイション ナイセリアゲノム配列およびそれらの使用方法
NZ545647A (en) * 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
MXPA02004283A (es) 1999-10-29 2002-10-17 Chiron Spa Peptidos antigenicos neisseriales.
DK1741784T3 (da) 1999-11-29 2010-05-25 Novartis Vaccines & Diagnostic 85kDa-antigen fra neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2393298C (en) 1999-12-02 2011-02-01 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
DK2270030T3 (da) * 2000-02-28 2012-08-13 Novartis Vaccines & Diagnostic Heterolog ekspression af Neisseria-proteiner
ES2206424T3 (es) 2000-06-08 2004-05-16 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Oligodesoxinucleotidos inmunoestimulantes.
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
PL226184B1 (pl) 2001-01-23 2017-06-30 Aventis Pasteur Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CA2441327A1 (en) 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
US6942802B2 (en) 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
RU2322451C2 (ru) 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
IL159210A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US20070020622A1 (en) * 2001-09-14 2007-01-25 Invitrogen Corporation DNA Polymerases and mutants thereof
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ATE419278T1 (de) 2002-03-26 2009-01-15 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
ES2775098T3 (es) 2002-10-11 2020-07-23 Glaxosmithkline Biologicals Sa Vacunas de polipéptidos para protección amplia contra linajes meningocócicos hipervirulentos
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Proteínas de superfície de neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20070148729A1 (en) 2003-01-15 2007-06-28 Farley John E Methods for increasing neisseria protein expression and compositions thereof
PT2191844E (pt) 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CN1867354A (zh) 2003-04-16 2006-11-22 惠氏控股有限公司 预防和治疗脑膜炎球菌疾病的新颖免疫原性组合物
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2551896A1 (en) 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1778725B1 (en) 2004-07-23 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
WO2006096701A2 (en) 2005-03-07 2006-09-14 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America Pharmaceutical liposomal compositions
PL1885734T3 (pl) 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
AU2006263936B2 (en) 2005-06-27 2010-05-20 Glaxosmithkline Biologicals S.A. Immunogenic composition
ES2443529T3 (es) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
ES2353516T3 (es) 2005-09-05 2011-03-02 Glaxosmithkline Biologicals S.A. Ensayo bactericida del suero para antisueros específicos de n. meningitidis.
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
BRPI0620418A2 (pt) 2005-12-23 2011-11-08 Glaxosmithkline Biolog Sa método para imunizar um paciente humano contra uma doença, usos de pelo menos dois e de pelo menos sete, dez, onze, treze ou quatorze conjugados e das vacinas, e, kit
DK2004225T3 (da) 2006-03-22 2012-08-06 Novartis Ag Programmer for vaccination med meningocockonjugater
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
JP5275983B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
CA2656474A1 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
CN101535493A (zh) 2006-07-27 2009-09-16 惠氏公司 用于生产重组蛋白质的高细胞密度补料-分批发酵方法
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101678094B (zh) 2007-06-04 2014-08-27 诺华股份有限公司 脑膜炎疫苗制剂
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20090035328A1 (en) 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2254594B1 (en) 2008-03-05 2015-06-03 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
WO2009143168A2 (en) 2008-05-19 2009-11-26 Novartis Ag Vaccine assays
EP2296699A4 (en) 2008-05-30 2013-11-13 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army POLYVALENT MENINGOCOCCULAR FUEL WITH NATIVE OUTER MEMBRANE VESICLES, METHOD OF MANUFACTURE AND USE
US8476032B2 (en) 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
CA2733943A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP5410084B2 (ja) * 2008-12-15 2014-02-05 川上産業株式会社 梱包箱及び箱状芯材
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
CN102711814A (zh) 2009-04-30 2012-10-03 奥克兰儿童医院及研究中心 一种嵌合h因子结合蛋白(fhbp)及其使用方法
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP3158225U (ja) * 2009-10-22 2010-03-25 王　文燦 折畳める物置袋
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CA2792687A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
EP2612148B1 (en) 2010-09-04 2019-06-12 GlaxoSmithKline Biologicals SA Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
US9965924B2 (en) 2013-07-15 2018-05-08 Ahmnon D. Moskowitz Methods, systems, and apparatus for playing multi-zone 21
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法

Also Published As

Publication number Publication date
EP2348035A2 (en) 2011-07-27
JP5997400B2 (ja) 2016-09-28
EP2371837A1 (en) 2011-10-05
CA2939781A1 (en) 2003-08-07
JP2014012002A (ja) 2014-01-23
JP5976880B2 (ja) 2016-08-24
EP2341063A2 (en) 2011-07-06
JP2005515771A (ja) 2005-06-02
EP2371837B1 (en) 2016-09-21
IL245955B (en) 2018-01-31
US9168293B2 (en) 2015-10-27
US20120308595A1 (en) 2012-12-06
EP2341062A3 (en) 2011-09-14
KR20100028657A (ko) 2010-03-12
BR0212999A (pt) 2006-05-23
CA2849427C (en) 2016-10-04
HK1178800A1 (zh) 2013-09-19
EP2371836A1 (en) 2011-10-05
US8563006B2 (en) 2013-10-22
AU2012202916A1 (en) 2012-06-07
BE2017C055I2 (en:Method) 2022-02-01
US9132182B2 (en) 2015-09-15
US20190151431A1 (en) 2019-05-23
PT2371838E (pt) 2016-03-23
CN102755631A (zh) 2012-10-31
EP2371838A1 (en) 2011-10-05
EP2366707A1 (en) 2011-09-21
JP2016165275A (ja) 2016-09-15
IL245956B (en) 2019-02-28
EP2366707B1 (en) 2016-09-21
NL300896I2 (nl) 2018-04-06
EP2348034A3 (en) 2011-09-21
MX339524B (es) 2016-05-30
MXPA04003356A (es) 2004-11-29
EP2341063A3 (en) 2011-09-14
ES2549764T3 (es) 2015-11-02
DK2348035T3 (en) 2015-04-20
PT2371836T (pt) 2017-02-17
EP2351767A2 (en) 2011-08-03
EP1442047A4 (en) 2005-06-01
ES2615206T3 (es) 2017-06-05
EP2371838B1 (en) 2015-12-16
EP2343308B1 (en) 2015-02-18
US20150335724A1 (en) 2015-11-26
US20200138933A1 (en) 2020-05-07
AU2009213040A1 (en) 2009-10-08
EP1442047B1 (en) 2016-03-16
EP2348036A3 (en) 2011-08-03
BE2017C056I2 (en:Method) 2022-02-01
PT2341063E (pt) 2015-10-29
EP2348035A3 (en) 2011-09-14
ES2603531T3 (es) 2017-02-28
CA2894296A1 (en) 2003-08-07
DK2332961T3 (en) 2016-10-03
FR17C1043I1 (en:Method) 2017-12-22
US20170173140A1 (en) 2017-06-22
US9757444B2 (en) 2017-09-12
ES2781213T3 (es) 2020-08-31
JP5923070B2 (ja) 2016-05-24
ES2562811T3 (es) 2016-03-08
BRPI0212999B1 (pt) 2020-04-28
LUC00040I1 (en:Method) 2017-10-16
US10300122B2 (en) 2019-05-28
EP2341062A2 (en) 2011-07-06
FR17C1043I2 (fr) 2018-12-07
US9623101B2 (en) 2017-04-18
EP2348036B1 (en) 2015-12-16
EP2332961A2 (en) 2011-06-15
CA2849427A1 (en) 2003-08-07
JP5404441B2 (ja) 2014-01-29
EP2341062B1 (en) 2017-03-29
BRPI0212999B8 (pt) 2021-07-27
CA2939781C (en) 2022-09-13
IL245956A0 (en) 2016-07-31
CN105617372A (zh) 2016-06-01
FR17C1044I2 (fr) 2018-12-07
ES2561430T3 (es) 2016-02-26
EP3199539A1 (en) 2017-08-02
US20120034261A1 (en) 2012-02-09
PT3199539T (pt) 2020-04-01
EP2343308A2 (en) 2011-07-13
AU2009213040B2 (en) 2012-03-01
IL233545A (en) 2017-10-31
LUC00042I1 (en:Method) 2017-10-16
NL300896I1 (nl) 2017-10-20
DK2341062T3 (en) 2017-05-08
AU2009213040C1 (en) 2012-10-11
AU2012202916B2 (en) 2013-08-01
CN102836426B (zh) 2016-09-28
ES2593360T3 (es) 2016-12-07
US8563007B1 (en) 2013-10-22
LU92786I2 (fr) 2015-11-02
JP2017025061A (ja) 2017-02-02
EP3199539B1 (en) 2020-03-11
EP2351767A3 (en) 2011-09-14
EP2351767B1 (en) 2015-08-26
ES2568895T3 (es) 2016-05-05
WO2003063766A3 (en) 2004-01-08
CN102755631B (zh) 2015-11-25
WO2003063766A2 (en) 2003-08-07
EP2348034A2 (en) 2011-07-27
LUC00042I2 (en:Method) 2017-12-20
BE2017C057I2 (en:Method) 2022-02-01
US20060257413A1 (en) 2006-11-16
US20120294880A1 (en) 2012-11-22
FR17C1042I1 (en:Method) 2017-12-22
IL245955A0 (en) 2016-07-31
CA2918207C (en) 2016-10-18
EP2348034B1 (en) 2016-11-02
FR15C0056I1 (en:Method) 2015-09-11
DK2351767T3 (en) 2015-10-26
PT2348035E (pt) 2015-03-25
CN1578785B (zh) 2013-03-13
EP2341063B1 (en) 2015-08-26
ES2625876T3 (es) 2017-07-20
DK2371838T3 (en) 2016-02-22
HK1178429A1 (zh) 2013-09-13
PT2341062T (pt) 2017-06-02
US20110076299A1 (en) 2011-03-31
NL300897I1 (nl) 2017-10-20
EP2343308A3 (en) 2011-07-27
MX349481B (es) 2017-07-31
EP2332961B1 (en) 2016-07-27
CN1578785A (zh) 2005-02-09
US20120201844A1 (en) 2012-08-09
PT2348036E (pt) 2016-03-09
ES2609039T3 (es) 2017-04-18
IL161052A0 (en) 2004-08-31
DK2371836T3 (en) 2017-02-20
LUC00041I1 (en:Method) 2017-10-16
EP1442047A2 (en) 2004-08-04
LUC00041I2 (en:Method) 2017-12-20
AU2012202916C1 (en) 2017-06-08
US20150216960A1 (en) 2015-08-06
CN102836426A (zh) 2012-12-26
KR20100121699A (ko) 2010-11-18
LUC00040I2 (en:Method) 2017-12-20
FR17C1042I2 (fr) 2018-12-07
US20130259889A1 (en) 2013-10-03
FR17C1044I1 (en:Method) 2017-12-22
DK2343308T3 (en) 2015-03-30
US8101194B2 (en) 2012-01-24
ES2532640T3 (es) 2015-03-30
IL233545A0 (en) 2014-08-31
KR20110117726A (ko) 2011-10-27
US11116829B2 (en) 2021-09-14
KR101099916B1 (ko) 2011-12-28
KR20040066793A (ko) 2004-07-27
CA2463476C (en) 2017-09-12
EP2348036A2 (en) 2011-07-27
EP2348035B1 (en) 2015-02-18
PT2332961T (pt) 2016-09-28
PT2343308E (pt) 2015-03-25
ES2549765T3 (es) 2015-11-02
US20120301496A1 (en) 2012-11-29
PT2351767E (pt) 2015-10-30
CA2918207A1 (en) 2003-08-07
AU2018203627A1 (en) 2018-06-07
US9107873B2 (en) 2015-08-18
ES2532639T3 (es) 2015-03-30
EP2332961A3 (en) 2011-07-27
FR15C0056I2 (fr) 2016-06-03
NL300897I2 (nl) 2018-04-06
JP2010162023A (ja) 2010-07-29
IL161052A (en) 2015-04-30
JP2015214545A (ja) 2015-12-03
CA2463476A1 (en) 2003-08-07
KR101068318B1 (ko) 2011-09-28
KR101215664B1 (ko) 2012-12-26
DK3199539T3 (da) 2020-04-27
DK2348036T3 (en) 2016-02-22
DK2341063T3 (en) 2015-10-26
EP2371836B1 (en) 2016-12-14
NL300899I2 (nl) 2018-04-06
NL300899I1 (nl) 2017-10-20
CA2894296C (en) 2018-05-01

Similar Documents

Publication Publication Date Title
ES2603532T3 (es) Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
Ala'Aldeen et al. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design
EP0462210B1 (en) Vaccines for nontypable haemophilus influenzae
AU746442B2 (en) UspA1 and UspA2 antigens of Moraxella catarrhalis
CN102580072A (zh) 组合式奈瑟球菌组合物
EP1378245A2 (en) Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis. Their use in a vaccine
ES2270523T3 (es) Antigenos de superficie y proteinas utiles en composiciones para la diagnosis y prevencion de la enfermedad de lyme.
CZ217292A3 (en) Immunogen against mammals lyme borreliosis
US5656451A (en) OspE, OspF, and S1 polypeptides in borrelia burgdorferi
HU220116B (hu) A Neisseria meningitidis transzferin-receptorának Tbp2-fragmentumai
US8313749B2 (en) P. gingivalis vaccine
EP1003874B1 (en) Neisseria lactoferrin binding protein
EP1200122B1 (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
CN101448522A (zh) 包含蛋白质nmb0938的药物组合物
EP1535928B1 (en) Vaccine compositions comprising Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis
US6716591B1 (en) B. burgdorferi polypeptides
RU2244749C2 (ru) Композиция для лечения или профилактики инфекции, вызванной бактерией neisseria
JPH10504455A (ja) ボレリア・ブルグドルフェリのＯｓｐＧを含有するワクチン
CN101443037A (zh) 包含蛋白质nma0939的药物组合物
CZ2000530A3 (cs) Protein Neisserie vázající laktoferin
CZ462199A3 (cs) Povrchové antigeny a proteiny použitelné v prostředcích pro diagnostiku a prevenci Lymské boreliosy